Document Detail


EGFR-directed monoclonal antibodies in non-small cell lung cancer.
MedLine Citation:
PMID:  23300028     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Several monoclonal antibodies directed against the epidermal growth factor receptor (EGFR) have been evaluated in patients with non-small cell lung cancer (NSCLC). Cetuximab, a chimeric monoclonal antibody, has been studied in combination with first-line chemotherapy in phase II and two phase III trials in patients with advanced NSCLC. The phase III FLEX trial demonstrated an increase in survival for cisplatin/vinorelbine plus cetuximab compared to chemotherapy alone in patients with advanced EGFR-expressing NSCLC. Cetuximab added to carboplatin/paclitaxel failed to improve progression-free survival in the BMS099 phase III trial. However, a meta-analysis of four randomized trials confirmed a significant survival benefit for platinum-based chemotherapy plus cetuximab compared to chemotherapy alone. High EGFR expression of tumor cells was then shown to predict the benefit of cetuximab, whereas KRAS mutations and EGFR fluorescent in situ hybridization analysis were without predictive value. Matuzumab and panitumumab have also been studied in phase II trials. Necitumumab, a fully human monoclonal antibody, is currently evaluated in combination with chemotherapy in two phase III trials in patients with advanced NSCLC. Cetuximab is also studied in combination with chemoradiotherapy in patients with locally advanced NSCLC.
Authors:
Robert Pirker
Related Documents :
23423768 - Egfr-targeted therapy for non-small cell lung cancer: focus on egfr oncogenic mutation.
217528 - Primary oat cell carcinoma of the larynx: a case report and review of the literature.
24926548 - A randomized, phase 2 trial of docetaxel with or without px-866, an irreversible oral p...
23649448 - Treatment of small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: a...
24729118 - Haematological complete remission by ponatinib and bortezomib in a patient with relapse...
17309608 - The predicted probability of having positive non-sentinel lymph nodes in patients who r...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-9
Journal Detail:
Title:  Targeted oncology     Volume:  -     ISSN:  1776-260X     ISO Abbreviation:  Target Oncol     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-9     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101270595     Medline TA:  Target Oncol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Department of Medicine I, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria, robert.pirker@meduniwien.ac.at.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Predicting the Impact of Single-Nucleotide Polymorphisms in CDK2-Flavopiridol Complex by Molecular D...
Next Document:  The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to sec...